Latest news with #Zepbound®
Business Wire
6 days ago
- Health
- Business Wire
AgelessRx Broadens GLP-1 Weight Care Options to Advance Longevity-First Healthcare
ANN ARBOR, Mich.--(BUSINESS WIRE)-- AgelessRx, a pioneer in longevity and telehealth solutions, is expanding its suite of GLP-1 offerings to better serve customers seeking sustainable, medically guided solutions. The updated offering includes access to Zepbound® via LillyDirect® and the introduction of Compounded Liraglutide + B12. This expansion reflects AgelessRx's mission to make science-backed, personalized longevity care more accessible, offering a range of clinically appropriate GLP-1 therapies that support better metabolic health and, in turn, potentially improve lifespan and healthspan. Weight is one of the most modifiable risk factors affecting healthy aging. Elevated BMI is strongly associated with reduced life expectancy, insulin resistance, and age-related disease. For people who've struggled to achieve a lower BMI through lifestyle alone, GLP-1s have been a promising solution. The GLP-1 category is projected to exceed $322.85 billion globally by 2034, with rapid growth at 21.3% CAGR, driven by public demand for obesity and metabolic health solutions that target the biology behind weight gain. As a longevity-first platform, AgelessRx is uniquely positioned to guide customers through safe, personalized use of these therapies as part of a broader preventative care model. AgelessRx clinicians will evaluate eligibility and, if appropriate, prescribe Zepbound® for fulfillment via LillyDirect®, Eli Lilly's direct-to-patient pharmacy. AgelessRx will provide full prescription management and clinical oversight for $50/month, including titration guidance, side-effect monitoring, as well as ongoing care and education to provide an additional layer of longevity-focused support. If eligible, patients can access Zepbound® single-dose vials directly from LillyDirect®, starting at $349/month. AgelessRx is not affiliated with Eli Lilly or LillyDirect® and serves solely as the prescribing and care coordination provider to support patients through their treatment. Recent topline results from the SURMOUNT-5 trial show the impact of Zepbound® (tirzepatide): −20.2% average weight reduction with tirzepatide compared to -13.7% with semaglutide 47% greater relative reduction in weight Over 31% of patients on tirzepatide achieved ≥25% weight loss While full peer-reviewed results are pending, these findings reinforce growing evidence that dual GIP/GLP-1 receptor agonists like tirzepatide may offer significant metabolic benefits. In addition to supporting access to Zepbound® via LillyDirect®, AgelessRx has also introduced Compounded Liraglutide + B12, a daily GLP-1 injectable. These two new treatments join several other metabolic health solutions, all of which are prescribed following a comprehensive evaluation and personalized plan, providing eligible customers with a diverse range of treatment options based on affordability, clinical fit, safety, and overall health goals. For additional information about AgelessRx, please visit *AgelessRx has no affiliation or partnership with Eli Lilly or LillyDirect®. AgelessRx's role is to provide clinical evaluation and prescription management for patients who meet the medical criteria for Zepbound®. Medication fulfillment is handled solely by LillyDirect®. About AgelessRx AgelessRx is at the forefront of the longevity revolution, offering clinically validated, cutting-edge solutions and preventive treatments aimed at extending life expectancy and enhancing quality of life. AgelessRx also continues to advance the field of longevity science by conducting ongoing research and clinical trials. Through its online platform, AgelessRx provides easy access to innovative healthcare services, with an emphasis on customer satisfaction, affordability, and the pursuit of a future where extended healthspan is a reality for everyone. Follow AgelessRx on Instagram, X, and Facebook.
Yahoo
6 days ago
- Business
- Yahoo
AgelessRx Broadens GLP-1 Weight Care Options to Advance Longevity-First Healthcare
New offerings, including Zepbound® via LillyDirect® and Compounded Liraglutide + B12, reflect AgelessRx's mission to make clinically validated, metabolic health solutions more accessible. ANN ARBOR, Mich., May 29, 2025--(BUSINESS WIRE)--AgelessRx, a pioneer in longevity and telehealth solutions, is expanding its suite of GLP-1 offerings to better serve customers seeking sustainable, medically guided solutions. The updated offering includes access to Zepbound® via LillyDirect® and the introduction of Compounded Liraglutide + B12. This expansion reflects AgelessRx's mission to make science-backed, personalized longevity care more accessible, offering a range of clinically appropriate GLP-1 therapies that support better metabolic health and, in turn, potentially improve lifespan and healthspan. Weight is one of the most modifiable risk factors affecting healthy aging. Elevated BMI is strongly associated with reduced life expectancy, insulin resistance, and age-related disease. For people who've struggled to achieve a lower BMI through lifestyle alone, GLP-1s have been a promising solution. The GLP-1 category is projected to exceed $322.85 billion globally by 2034, with rapid growth at 21.3% CAGR, driven by public demand for obesity and metabolic health solutions that target the biology behind weight gain. As a longevity-first platform, AgelessRx is uniquely positioned to guide customers through safe, personalized use of these therapies as part of a broader preventative care model. AgelessRx clinicians will evaluate eligibility and, if appropriate, prescribe Zepbound® for fulfillment via LillyDirect®, Eli Lilly's direct-to-patient pharmacy. AgelessRx will provide full prescription management and clinical oversight for $50/month, including titration guidance, side-effect monitoring, as well as ongoing care and education to provide an additional layer of longevity-focused support. If eligible, patients can access Zepbound® single-dose vials directly from LillyDirect®, starting at $349/month. AgelessRx is not affiliated with Eli Lilly or LillyDirect® and serves solely as the prescribing and care coordination provider to support patients through their treatment. Recent topline results from the SURMOUNT-5 trial show the impact of Zepbound® (tirzepatide): −20.2% average weight reduction with tirzepatide compared to -13.7% with semaglutide 47% greater relative reduction in weight Over 31% of patients on tirzepatide achieved ≥25% weight loss While full peer-reviewed results are pending, these findings reinforce growing evidence that dual GIP/GLP-1 receptor agonists like tirzepatide may offer significant metabolic benefits. In addition to supporting access to Zepbound® via LillyDirect®, AgelessRx has also introduced Compounded Liraglutide + B12, a daily GLP-1 injectable. These two new treatments join several other metabolic health solutions, all of which are prescribed following a comprehensive evaluation and personalized plan, providing eligible customers with a diverse range of treatment options based on affordability, clinical fit, safety, and overall health goals. For additional information about AgelessRx, please visit *AgelessRx has no affiliation or partnership with Eli Lilly or LillyDirect®. AgelessRx's role is to provide clinical evaluation and prescription management for patients who meet the medical criteria for Zepbound®. Medication fulfillment is handled solely by LillyDirect®. About AgelessRx AgelessRx is at the forefront of the longevity revolution, offering clinically validated, cutting-edge solutions and preventive treatments aimed at extending life expectancy and enhancing quality of life. AgelessRx also continues to advance the field of longevity science by conducting ongoing research and clinical trials. Through its online platform, AgelessRx provides easy access to innovative healthcare services, with an emphasis on customer satisfaction, affordability, and the pursuit of a future where extended healthspan is a reality for everyone. Follow AgelessRx on Instagram, X, and Facebook. View source version on Contacts Media contact: JackTaylor PRagelessrx@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-04-2025
- Health
- Yahoo
Nurx Works with Gifthealth to Streamline Access to Lilly's Medication Zepbound®
NEW YORK, April 9, 2025 /PRNewswire/ -- Nurx, a leading telehealth platform specializing in women's health, is excited to announce an integration agreement with Gifthealth, Eli Lilly and Company's LillyDirect® pharmacy provider, for Zepbound® (tirzepatide) single-dose vials to simplify prescription access. The arrangement will streamline access to the vials for clinically-eligible Nurx patients with an on-label prescription, ensuring they have a more seamless way to receive chronic weight management treatment. Obesity and overweight affect more than 2 out of 3 women over the age of 20 in the United States and is a risk that increases with age. What's more, 11.5% of women have severe obesity, a higher rate than in men. Overweight and obesity have profound health implications, increasing the risks of cardiovascular disease, type-2 diabetes, certain cancers, and complications during pregnancy. This is why addressing overweight and obesity is crucial for improving women's health overall. However, losing weight and keeping it off can be challenging: studies show that only 1 in 10 adults with overweight and obesity achieve weight loss of 5% or more each year. Recognizing these challenges, Nurx is committed to providing women with effective, evidence-based weight management solutions. This integration with Gifthealth will streamline access to Zepbound®, an FDA-approved medication for obesity and chronic weight management, for clinically-eligible patients with an on-label prescription from a Nurx-affiliated provider. This integration arrangement also underscores Nurx's dedication to empowering women with the tools and support necessary to achieve their health goals. As demand for obesity and chronic weight management medications like Zepbound® continues to rise, Nurx is committed to providing comprehensive telehealth care for women navigating weight management. By integrating Gifthealth's pharmacy fulfillment capabilities, Nurx patients will benefit from streamlined access to Zepbound® vials, and can take advantage of Gifthealth's transparent pricing and nationwide delivery — key factors in making obesity care more accessible. "At Nurx, we believe that every woman deserves access to the healthcare solutions that best fit her needs — including safe and effective weight management medications," said Rajani Rao, Chief Business Officer at Nurx. "This integration agreement with Gifthealth allows us to streamline barriers to access, ensuring women can get the medication they need, and pair it with Nurx's comprehensive approach to weight management, which provides ongoing access to physicians and support in making lifestyle changes." Gifthealth has been at the forefront of prescription innovation. This new integration agreement with Nurx will help streamline the prescription fulfillment process for weight management treatments, reinforcing both companies' missions to provide affordable, high-quality care. "We are excited to work with providers such as Nurx to streamline access to authentic Zepbound® vials for women nationwide," said Robert Hoppe, EVP of Life Sciences at Gifthealth. "Our goal is to remove cost and logistical barriers to essential medications, and through these integrations, we can help more patients get the care they need." About Nurx by Thirty MadisonNurx is the leading women's healthcare company making high-quality, judgment-free care accessible and affordable for millions. By removing barriers like cost, stigma, and provider shortages, we provide convenient, personalized treatment across 20+ conditions, including reproductive and sexual health, dermatology, mental health, migraine, hair loss, and weight management. With over 2 million patients served and more than 600,000 actively receiving care, Nurx connects patients directly with trusted healthcare providers and delivers treatment right to their doorstep — ensuring ongoing, specialty-level support that evolves with their needs. About Thirty Madison Thirty Madison offers end-to-end, high-quality virtual specialized care for patients experiencing a range of conditions. Through its brands — Keeps for men's hair loss, Cove for migraine, and Nurx for women's health — Thirty Madison supports the unique needs of its patients with ongoing access to personalized care and specialty-level telemedicine. Thirty Madison's unique care model delivers care that is accessible, affordable, and focused on improving outcomes. Learn more at About Gifthealth Gifthealth is a digital pharmacy solution founded in 2020, focused on simplifying the prescription process for patients, providers, and manufacturers. By leveraging technology, Gifthealth ensures cost-effective medication access, with a mission to improve adherence and health outcomes. Learn more at Media Contact:Stephanie HallPitch Public Relations480.216.5433 | Stephanie@ View original content to download multimedia: SOURCE Nurx
Associated Press
18-03-2025
- Health
- Associated Press
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R)
More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound® As previously announced, oral DehydraTECH-tirzepatide also reduced adverse events by 47% compared to injected Zepbound® Lexaria's oral capsules worthy of expanded investigation as a viable alternative to injected tirzepatide. KELOWNA, BC / ACCESS Newswire / March 18, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms, is pleased to announce positive pharmacokinetic ('PK') results from Human Study #3 or GLP-1-H24-3 (the 'Study'), comparing an oral version of DehydraTECH-processed Zepbound® ('DehydraTECH-tirzepatide') to conventional injected Zepbound®. Zepbound® is currently only available as a once-weekly injection for weight loss. It is not sold by Eli Lilly in any oral format. Lexaria's Study was designed to discover whether the active drug within Zepbound® - tirzepatide - could be administered using Lexaria's patented DehydraTECH drug delivery technology via simple oral capsules in order to deliver a useful quantity of tirzepatide into the human bloodstream, as well as provide a viable alternative to disliked injections. The results were unexpectedly positive, showing that orally delivered DehydraTECH-tirzepatide reached roughly equal end of Study blood-concentration levels as the injected drug. During the 8-day Study, data was successfully collected from 10 people who were dosed with a single weekly injection of Zepbound®, and from 9 people who were dosed daily over the same one-week duration with DehydraTECH-tirzepatide capsules. In general, the peak levels of blood delivery of the injected Zepbound® were, for the most part, higher than that of the DehydraTECH-tirzepatide, but not in all cases. The injected Zepbound® typically reached a peak level within blood on the 2nd day of the Study and subsequently declined. Conversely, the DehydraTECH-tirzepatide blood levels increased steadily and more consistently each day of the Study, avoided any abrupt peaks or declines, and were generally still rising on Day 8, the final day of the Study. Of those receiving the Zepbound® injection, 8 of 10 people (80%) experienced peak levels on Day 2 of the Study and subsequently experienced declining levels, whereas of those receiving the DehydraTECH-tirzepatide, 4 of 8 people (50%) experienced their peak levels on the final day of the Study, indicating that their levels were still rising at the conclusion of the Study. As announced on January 14, 2025, during the Study DehydraTECH-tirzepatide also evidenced reduced side effects, while achieving comparable concluding glycemic performance indicators. The injected Zepbound® produced a total of 38 adverse events during the Study, whereas the oral DehydraTECH-tirzepatide produced only 20, or 47% fewer, adverse events along with a 54% reduction in gastrointestinal side effects as compared to the Zepbound®. Furthermore, the DehydraTECH-tirzepatide capsules produced a comparable reduction in blood glucose together with a similar increase in blood insulin from baseline to Day 8 of the Study. 'Lexaria's first-ever study of oral DehydraTECH-tirzepatide has far exceeded our expectations,' said Richard Christopher, CEO of Lexaria. 'We have succeeded in demonstrating all 3 of our main objectives; reduced side effects with similar efficacy and similar blood-delivery levels as compared to injected tirzepatide by the end of the Study. Our ongoing 12-week study in Australia is well positioned to further evaluate the effectiveness of DehydraTECH over an extended dosing duration and potentially establish Lexaria as a global player in oral delivery within the fast-growing GLP-1 weight loss and diabetes control markets.' All the results of this study - reduced side effects, comparable end of Study blood sugar control and measured drug in bloodstream - are extremely encouraging and support our decision to further evaluate DehydraTECH-tirzepatide in our ongoing Australian Phase 1b registrational study (GLP-1-H24-4). In that 12-week study, DehydraTECH-tirzepatide will be dosed at the same 20mg/day level utilized in Human Study #3 for the initial 4 weeks of treatment, escalating further to 40mg/day over the last 8 weeks of treatment, thereby allowing Lexaria to potentially demonstrate further increased delivery and efficacy relative to the present Study. Lexaria looks forward to the opportunity to assess the very important steady-state blood levels which DehydraTECH-tirzepatide administered via its oral capsules will achieve over an extended dosing duration in study GLP-1-H24-4 as they relate to published figures for sustained injectable tirzepatide dosing, given the fact that blood levels from DehydraTECH-tirzepatide witnessed in the present Study were continuing to ascend at Day 8. There is no oral version of tirzepatide sold in the world today, as it is administered only by injection (Zepbound® and Mounjaro®). Lexaria has previously completed other research with oral DehydraTECH-processed semaglutide, sold by Novo Nordisk®, which is the only GLP-1 drug that is currently available as both an oral (Rybelsus®) and an injectable (Ozempic® and Wegovy®). This research yielded similar findings wherein Lexaria's DehydraTECH-processed semaglutide evidenced certain improvements in oral delivery compared to Rybelsus®. Lexaria believes that an effective oral version of tirzepatide with fewer adverse events than the current injectable versions, could be highly valued. As noted, Rybelsus® is the only orally delivered GLP-1 drug on the market today. Rybelsus® uses a proprietary drug delivery technology called salcaprozate sodium ('SNAC'), that Novo Nordisk paid US$1.8 billion to acquire, to enable efficacy in an oral delivery format. Lexaria notes that, of course, there was no SNAC present in either the Zepbound® or in Lexaria's DehydraTECH-tirzepatide in the present Study, showcasing that Lexaria's wholly owned DehydraTECH technology has now demonstrated its ability to successfully deliver 3 of the world's best-selling weight-loss and diabetes control drugs: tirzepatide, liraglutide, and semaglutide across its animal and human GLP-1 studies conducted to-date. About the Study Many design characteristics of the Study, also referred to as Study GLP-1-H24-3, are similar to Lexaria's initial GLP-1 human pilot study #1, investigating the dual agonist GLP-1/GIP drug tirzepatide in this Study instead of the GLP-1 agonist semaglutide from human pilot study #1. The DehydraTECH-tirzepatide test articles were compound formulated using Zepbound®, strictly for research purposes, and dosed orally to the subjects under fasted conditions. The Study was designed to measure tolerability and side effects, blood levels of tirzepatide, and blood glucose and insulin levels. The DehydraTECH-tirzepatide composition was formulated at a strength of 20 mg tirzepatide administered orally daily for seven days followed through to the end of the eighth day post-dosing. The Zepbound® formulation had a strength of 2.5 mg tirzepatide administered once via injection with the subject monitored over the same eight-day total duration. Blood samples were taken multiple times during the first 12 hours post dosing on the first day of each treatment phase, with single blood samples taken daily thereafter through to a final blood draw taken 24 hours after the end of dosing (i.e., on the eighth day of the Study); and, all subjects were dosed under fasted conditions with a standardized meal fed to the test subjects at a point in time after dosing. Subjects were dosed with each test article following a randomized, cross over study design across two study phases, separated by a 4-6 week washout duration. About Lexaria Bioscience Corp. & DehydraTECH DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 48 patents granted and additional patents pending worldwide. For more information, please visit CAUTION REGARDING FORWARD-LOOKING STATEMENTS This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as 'anticipate,' 'if,' 'believe,' 'plan,' 'estimate,' 'expect,' 'intend,' 'may,' 'could,' 'should,' 'will,' and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. Phone: 250-765-6424, ext 202
Associated Press
27-01-2025
- Business
- Associated Press
Kailera Therapeutics Appoints Jamie Coleman as Chief Commercial Officer
BOSTON and SAN DIEGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions, today announced the appointment of Jamie Coleman as Chief Commercial Officer. In this role, Ms. Coleman will be responsible for establishing and executing Kailera's overall commercial strategy for the Company's advanced clinical-stage product candidates for the treatment of obesity and related conditions. She joins Kailera from Eli Lilly where she held key roles in brand strategy, consumer marketing, and global commercial leadership across therapeutic areas, including most recently serving as Vice President, U.S. Brand Leader for Zepbound®. 'We are excited to welcome Jamie to the team as we progress KAI-9531 toward a global Phase 3 clinical program, laying the groundwork for its future commercialization,' said Ron Renaud, President and Chief Executive Officer, Kailera. 'With an exceptional track record of results-driven commercial leadership, including her recent achievements in launching a blockbuster brand in the dynamic obesity space, Jamie's expertise in building and leading high-performing teams will be instrumental in helping us achieve our goal of delivering next-generation therapies to people who need them.' 'Obesity is one of the most urgent health challenges of our time, and I'm passionate about leveraging my experience in building brands, driving cross-functional collaboration, and delivering impactful results to ultimately improve the lives of people living with obesity,' said Jamie Coleman, Chief Commercial Officer, Kailera. 'I share the team's commitment to patient-centered solutions and I'm excited to contribute to advancing Kailera's broad pipeline of potentially best-in-class therapies.' Jamie is an accomplished commercial leader with nearly 25 years of experience in leading transformative, global healthcare brands. During her 17-year tenure at Eli Lilly, she held commercial leadership roles over the product lifecycle in a range of therapeutic areas, including obesity, diabetes, and oncology. Most recently, Jamie served as Vice President, U.S. Brand Leader for Zepbound® where she executed an accelerated product launch, delivering a market-leading brand for the treatment of obesity. Previously, she was U.S. Brand Leader for Trulicity®, a treatment for type 2 diabetes, successfully navigating competitive dynamics while driving significant revenue growth. Jamie also led global brand strategy for Jardiance®, which became a leading product in the diabetes market, and oversaw the global commercial strategy and execution for Lartruvo® for the treatment of solid tumors. Additionally, she directed U.S. consumer marketing strategies for high-profile oncology treatments, and held roles at Pfizer and ZS Associates earlier in her career. Jamie holds an M.B.A. from the University of Chicago Booth School of Business and a B.B.A. in Marketing, International Business and Spanish from the University of Wisconsin. About Kailera Therapeutics Kailera Therapeutics (Kailera) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity and related conditions. Kailera's most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable GLP-1/GIP receptor dual agonist that has demonstrated positive results in Phase 2 trials in obesity and type 2 diabetes in China. The Company is also advancing a diversified pipeline leveraging several mechanisms and routes of delivery, including oral administration. Kailera's mission is to develop next-generation weight management therapies that give people the power to transform their lives and elevate their overall health. The Company is based in Waltham, MA and San Diego, CA. For more information, visit LinkedIn and X.
